Crypto news report · source clearly identified

Canary Capital Launches First U.S. Spot Staked TRX ETF (Ticker: TRXS)

Canary Capital Group LLC announced the launch of the Canary Staked TRX ETF (TRXS), offering spot exposure to TRX and staking rewards within a registered exchange‑traded structure.

Canary Capital Group LLC has introduced the Canary Staked TRX ETF (ticker: TRXS), the first U.S. spot‑based exchange‑traded fund that combines direct exposure to the TRON network’s native token, TRX, with the ability to earn staking rewards.

Fund Structure and Objectives

The ETF seeks to track the spot price of TRX while participating in TRON’s delegated proof‑of‑stake validation process. Net staking rewards are reflected in the fund’s net asset value, providing investors with potential additional returns beyond price appreciation.

TRON Network Highlights

TRON is a major blockchain for stablecoin activity, supporting over $94 billion of circulating Tether (USDT) and processing the highest USDT transfer volume of any chain, roughly $5.6 trillion year‑to‑date. The network is noted for its speed, scalability, and low transaction costs, serving decentralized finance, global payments, and dApp ecosystems.

Regulatory and Risk Considerations

The Canary Staked TRX ETF is not registered under the Investment Company Act of 1940, meaning it does not receive the same regulatory protections as traditional ETFs. Investors face risks including high volatility, potential loss of principal, staking‑related penalties such as slashing, and the lack of FDIC or SIPC insurance for the fund’s assets.

Market Perspective

Canary Capital’s CEO highlighted growing investor interest in blockchain infrastructure that underpins real‑world digital payments. TRON founder Justin Sun praised the ETF as a way to broaden investor participation in the network.

Source & attribution

News Source

Publisher
Bitcoin.com News
Original date
September 9, 2026, 4:11 PM
Original headline
Canary Capital Launches the First U.S. Spot Staked TRX ETF (Ticker: TRXS)
View original report ↗